Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Pacira BioSciences, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Pacira securities is from August 2, 2023, to August 8, 2024, and the lead plaintiff deadline is March 14, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Background - The lawsuit alleges that statements made by Pacira during the Class Period were misleading, particularly regarding the patent protections on Exparel, which were claimed to be critical for the company's growth [4]. - It is asserted that Pacira was aware of the weaknesses in its patent protections, particularly following a court ruling in favor of eVenus on June 6, 2023, yet continued to publicly affirm the strength of its patent [4]. - The lawsuit claims that when the true nature of the patent protections became known, investors suffered damages [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pacira BioSciences, Inc. following the invalidation of its '495 patent, which has led to significant stock price declines and investor losses [2][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $75,000 in Pacira between August 2, 2023, and August 8, 2024, to discuss their legal options [1]. - The firm is reminding investors of the March 14, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Pacira [2]. Group 2: Patent Invalidation Impact - On August 9, 2024, a New Jersey District Court invalidated Pacira's '495 patent, ruling that eVenus did not infringe on the patent due to obviousness and anticipation [4]. - The invalidation announcement surprised investors, leading to a dramatic stock price decline from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, representing a decline of over 47% in a single day [5]. Group 3: Class Action Details - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6]. - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, related to its main product Exparel, was ruled invalid by the court, which raises concerns about the validity of other patents held by the company [1]. - The invalidation of the '495 patent could result in more generic competitors entering the market and increased litigation costs for Pacira [1]. Financial Impact - Following the announcement of the patent ruling, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff applications set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2].

Group 1 - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [1][2] - The company has three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and ioveraº® [2] - Pacira is advancing the development of PCRX-201, a novel locally administered gene therapy for treating prevalent diseases like osteoarthritis [2] Group 2 - Pacira will participate in the Raymond James 46th Annual Institutional Investors Conference on March 5th at 10:25 AM ET [3] - The company will also attend the Barclays 27th Annual Global Healthcare Conference on March 12th at 8:00 AM ET [3]

Core Viewpoint - Wall Street analysts anticipate Pacira (PCRX) will report quarterly earnings of $0.86 per share, reflecting a year-over-year decline of 3.4%, while revenues are expected to be $184.01 million, an increase of 1.5% from the previous year [1] Earnings Projections - Changes in earnings projections are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [2] Analyst Forecasts - Analysts project that 'Revenue- Net product sales- EXPAREL' will reach $145.33 million, indicating a year-over-year change of +1% [4] - The consensus for 'Revenue- Net product sales- ZILRETTA' is $30.72 million, reflecting a +7% change from the year-ago quarter [4] - For 'Revenue- Net product sales- iovera', analysts estimate $6.36 million, which represents a +5.4% change from the previous year [4] Total Revenue Estimates - The combined estimate for 'Revenue- Total net product sales' is projected to be $183.38 million, indicating a year-over-year change of +2% [5] Stock Performance - Pacira shares have seen a -1.6% change over the past month, compared to a -1.8% move in the Zacks S&P 500 composite, with a Zacks Rank 1 (Strong Buy) suggesting expected outperformance in the near future [5]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit was initiated following a press release on August 9, 2024, where Pacira announced the invalidation of its U.S. Patent No. 11,033,495 related to its main product Exparel, which constitutes approximately 80% of the company's revenue [2] - The invalidation of the '495 patent raises concerns about the validity of other patents held by Pacira, potentially leading to increased competition from generic products and higher litigation costs [2] - Following the announcement, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Company Overview - Pacira BioSciences, Inc. (NASDAQ: PCRX) is primarily known for its product Exparel, which constitutes approximately 80% of its revenue [1]. Legal Issues - A lawsuit against eVenus resulted in the court ruling that Pacira's U.S. Patent No. 11,033,495 (the '495 patent) is not valid, meaning eVenus is not infringing on it [1]. - The invalidation of the '495 patent raises concerns about the validity of Pacira's other patents, potentially leading to more generic competitors entering the market and increased litigation costs [1]. Stock Performance - Following the announcement of the patent invalidation, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Legal Representation - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful business practices [3].

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 2, 2023, and August 8, 2024, following the invalidation of a key patent that significantly impacts its revenue [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by the alleged fraud during the specified period [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495, crucial for its product Exparel, was deemed invalid, leading to concerns about the validity of other patents and potential market competition from generics [2]. - Following the patent invalidation announcement, Pacira's stock plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Pacira BioSciences, Inc. is set to report its fourth quarter and full year financial results for 2024 on February 27, 2025, after U.S. market close, followed by a live conference call [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL®: a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA®: an extended-release injection for osteoarthritis knee pain management [3] - ioveraº®: a handheld device providing immediate, long-acting, drug-free pain control through cold temperature [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has adversely affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit is a response to a press release issued by Pacira on August 9, 2024, which announced the invalidation of its U.S. Patent No. 11,033,495 related to Exparel, a product that generates approximately 80% of the company's revenue [2] - Following the announcement, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request the Court to appoint them as lead plaintiff, although participation does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]